WOW. It was good that this figure was looked at more closely. The 57% figure is on-treatment TD-TI, not baseline TD-TI. Medically, these are completely different things.
Look at the wording of the poster, the swimlanes.
This explains the difference from the publication and the abstract.
Faron unequivocally provides misleading information in the press release. This is indeed a red flag!